(Reuters) – Florida has reached more than $ 878 million in deals with CVS Health Corp. and three drug companies to resolve their role in inciting an opioid epidemic in the third most populous state.
CVS will pay $ 484 million; Teva Pharmaceutical Industries Ltd. will pay $ 194.8 million; Abbvie Inc.’s Allergan unit will pay $ 134.2 million; and Endo International PLC will pay $ 65 million, Florida Attorney General Ashley Moody said in a statement.
Most of the money will be spent on opioid reduction. Teva will also provide $ 84 million of its generic Narcan nasal spray, which may temporarily reverse the effects of opioid overdoses.
All the companies denied the crime when they agreed to reconcile.
The deals were announced nine days after Rhode Island reached similar deals with Teva and Allergan, valued at $ 107 million.
CVS said that the settlement was in the best interests of all parties and that it would vigorously defend itself against other lawsuits concerning opioids. Teva said they “continue to actively negotiate a national settlement” of similar claims.
Abbvie and Endo were not immediately available for comment.